Scynexis (SCYX) Interest Expenses (2013 - 2025)
Scynexis' (SCYX) quarterly Interest Expenses came in at $173000.0 in Q1 2025, down 15.61% on a YoY basis from $205000.0 in Q1 2024, and down 18.01% quarter-over-quarter from $211000.0 in Q4 2024.
Analysis
Scynexis (SCYX) Interest Expenses (2013 - 2025) Analysis & Trends
Scynexis (SCYX) has reported Interest Expenses for 12 consecutive years, with $173000.0 the latest figure, recorded in Q1 2025.
- For the quarter ending Q1 2025, Interest Expenses fell 15.61% year-over-year to $173000.0; the trailing twelve-month figure through Dec 2025 stood at $173000.0 (down 79.06% YoY), and the FY2025 full-year result was $173000.0, down 79.11% from the prior year.
- Interest Expenses eased to $173000.0 in Q1 2025 per SCYX's latest filing, from $211000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $1.5 million in Q4 2022 and bottomed at $173000.0 in Q1 2025.
- Historically, Interest Expenses has averaged $705117.6 across 5 years, with a median of $445000.0 in 2021.
- The sharpest annual moves came in 2022 and 2024: Interest Expenses surged 394.86% in 2022, then slumped 85.83% in 2024.
- Over 5 years, Interest Expenses stood at $982000.0 in 2021, then jumped by 55.7% to $1.5 million in 2022, then sank by 85.48% to $222000.0 in 2023, then dropped by 4.95% to $211000.0 in 2024, then retreated by 18.01% to $173000.0 in 2025.
- According to Business Quant data, Interest Expenses over the past three periods registered $173000.0, $211000.0, and $213000.0 for Q1 2025, Q4 2024, and Q3 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | 173,000.00 |
| Dec 31, 2024 | 211,000.00 |
| Sep 30, 2024 | 213,000.00 |
| Jun 30, 2024 | 197,000.00 |
| Mar 31, 2024 | 205,000.00 |
| Dec 31, 2023 | 222,000.00 |
| Sep 30, 2023 | 212,000.00 |
| Jun 30, 2023 | 1.25 Mn |
| Mar 31, 2023 | 1.45 Mn |
| Dec 31, 2022 | 1.53 Mn |
| Sep 30, 2022 | 1.38 Mn |
| Jun 30, 2022 | 1.23 Mn |
| Mar 31, 2022 | 1.06 Mn |
| Dec 31, 2021 | 982,000.00 |
| Sep 30, 2021 | 1.02 Mn |
| Jun 30, 2021 | 445,000.00 |
| Mar 31, 2021 | 214,000.00 |
| Dec 31, 2020 | 322,000.00 |
| Sep 30, 2020 | 330,000.00 |
| Jun 30, 2020 | 602,000.00 |